| P2093 | author name string | Piet Geusens | |
| P2860 | cites work | Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation | Q24311588 |
| | Osteoprotegerin: a novel secreted protein involved in the regulation of bone density | Q24313918 |
| | osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification | Q24603266 |
| | Giant osteoclast formation and long-term oral bisphosphonate therapy | Q24626459 |
| | Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL | Q24682139 |
| | The role of osteoprotegerin in arthritis | Q24797889 |
| | Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis | Q28141482 |
| | Denosumab in postmenopausal women with low bone mineral density | Q28298728 |
| | Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation | Q28505419 |
| | The distribution of secondary growths in cancer of the breast. 1889 | Q29614314 |
| | Genetic regulation of osteoclast development and function | Q29617421 |
| | Osteoprotegerin treatment impairs remodeling and apparent material properties of callus tissue without influencing structural fracture strength | Q31157658 |
| | Noninvasive diagnosis of ruptured peripheral atherosclerotic lesions and myocardial infarction by antibody profiling | Q33355010 |
| | Comparison of effects of the bisphosphonate alendronate versus the RANKL inhibitor denosumab on murine fracture healing. | Q33385262 |
| | Effects of denosumab on bone mineral density and bone turnover in postmenopausal women | Q34656025 |
| | Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer | Q34813227 |
| | Bone and joint destruction in rheumatoid arthritis: what is really happening? | Q34866256 |
| | Identification of cell types responsible for bone resorption in rheumatoid arthritis and juvenile rheumatoid arthritis | Q35764588 |
| | Clinical development of anti-RANKL therapy | Q35901092 |
| | TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor | Q36380989 |
| | Preliminary evidence for a structural benefit of the new bisphosphonate zoledronic acid in early rheumatoid arthritis | Q56420412 |
| | Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: A twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial | Q57752107 |
| | Bisphosphonate-Associated Osteonecrosis of the Jaw: Report of a Task Force of the American Society for Bone and Mineral Research | Q58216587 |
| | Two-Year Treatment With Denosumab (AMG 162) in a Randomized Phase 2 Study of Postmenopausal Women With Low BMD | Q58971166 |
| | Suggested Sequential Mode of Control of Changes in Cell Behaviour in Adult Bone Remodelling | Q59076842 |
| | Randomized Active-Controlled Phase II Study of Denosumab Efficacy and Safety in Patients With Breast Cancer-Related Bone Metastases | Q62392239 |
| | Bisphosphonates for arthritis--a confusing rationale | Q73064627 |
| | Osteoclastogenesis inhibitory factor exhibits hypocalcemic effects in normal mice and in hypercalcemic nude mice carrying tumors associated with humoral hypercalcemia of malignancy | Q77690444 |
| | Advances in the biology and treatment of myeloma bone disease | Q78769316 |
| | Eating bone or adding it: the Wnt pathway decides | Q79751142 |
| | Targeted ablation of osteocytes induces osteoporosis with defective mechanotransduction | Q80432871 |
| | RANKL protein is expressed at the pannus-bone interface at sites of articular bone erosion in rheumatoid arthritis | Q82615147 |
| | The ratio of circulating osteoprotegerin to RANKL in early rheumatoid arthritis predicts later joint destruction | Q83880460 |
| | Bone quality--the material and structural basis of bone strength and fragility | Q36488553 |
| | Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. | Q36860987 |
| | Drug Insight: choosing a drug treatment strategy for women with osteoporosis-an evidence--based clinical perspective. | Q37132710 |
| | Quantum concept of bone remodeling and turnover: Implications for the pathogenesis of osteoporosis | Q39693077 |
| | Role of osteoblasts in hormonal control of bone resorption—A hypothesis | Q41551873 |
| | The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. | Q41649459 |
| | Expression of osteoprotegerin, receptor activator of NF-kappaB ligand (osteoprotegerin ligand) and related proinflammatory cytokines during fracture healing. | Q42505465 |
| | Preference and satisfaction with a 6-month subcutaneous injection versus a weekly tablet for treatment of low bone mass | Q43297986 |
| | The effect of a single dose of osteoprotegerin in postmenopausal women | Q43520860 |
| | Two year randomized controlled trial of etidronate in rheumatoid arthritis: changes in serum aminoterminal telopeptides correlate with radiographic progression of disease | Q44334690 |
| | Effects of high dose IV pamidronate on disease activity and bone metabolism in patients with active RA: a randomized, double-blind, placebo-controlled trial. | Q44579771 |
| | A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women | Q46133598 |
| | The deceiving appearances of osteoclasts | Q46178064 |
| | Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy | Q46312540 |
| | Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial | Q46393065 |
| | Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial | Q46551911 |
| | Effects of denosumab on the geometry of the proximal femur in postmenopausal women in comparison with alendronate | Q46582756 |
| | A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer | Q46952812 |
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | osteoporosis | Q165328 |
| | peptide | Q172847 |
| | globulins | Q321710 |
| | monoclonal antibody | Q422248 |
| | blood proteins | Q425056 |
| | postmenopausal osteoporosis | Q55950294 |
| P304 | page(s) | 241-250 | |
| P577 | publication date | 2009-06-09 | |
| P1433 | published in | Clinical Interventions in Aging | Q5133768 |
| P1476 | title | Emerging treatments for postmenopausal osteoporosis - focus on denosumab | |
| P478 | volume | 4 | |